Substantially pure olmesartan medoxomil and processes for its preparation
A process for purifying olmesartan medoxomil is provided comprising (a) dissolving olmesartan medoxomil in a solvent system comprising a ketone and at least one solvent selected from the group consisting of an alcohol-containing solvent, an ester-containing solvent and mixtures thereof to obtain a solution; and (b) recovering substantially pure olmesartan medoxomil. Also disclosed is substantially pure olmesartan medoxomil and pharmaceutical compositions containing same.
1 . A process for purifying olmesartan medoxomil comprising (a) dissolving olmesartan medoxomil in a solvent system comprising a ketone and at least one solvent selected from the group consisting of an alcohol-containing solvent, an ester-containing solvent and mixtures thereof to obtain a solution; and (b) recovering substantially pure olmesartan medoxomil.
2 . The process of claim 1 , wherein the solution is formed at an elevated temperature.
3 . The process of claim 1 , wherein step (a) comprises heating the olmesartan medoxomil dissolved in the solvent system to a temperature of about 30° C. to about 100° C.
4 . The process of claim 1 , wherein the solvent system comprises a ketone and an ester-containing solvent.
5 . The process of claim 4 , wherein the ketone is a ketone having 3 to about 12 carbon atoms and the ester-containing solvent is an acetate.
6 . The process of claim 1 , wherein the solvent system comprises acetone and ethyl acetate.
7 . The process of claim 1 , wherein the concentration of the ketone in the solution is about 5 to about 10% weight per volume (w/v) and the concentration of the ester-containing solvent in the solution is about 10 to about 20% w/v.
8 . The process of claim 2 , wherein the step (b) comprises precipitating the olmesartan medoxomil; and (d) recovering substantially pure olmesartan medoxomil
9 . The process of claim 8 , wherein precipitating is induced by cooling the solution from the elevated temperature.
10 . The process of claim 9 , wherein the step of precipitating comprises cooling the solution to a temperature of about 0° C. to about 30° C.
11 . The process of claim 9 , wherein the step of precipitating comprises cooling the solution to a temperature of about 10° C. to about 25° C.
12 . The process of claim 8 , further comprising drying the purified olmesartan medoxomil.
13 . The process of claim 1 , further comprising heating the solution to an elevated temperature; cooling the solution to induce precipitation of the olmesartan medoxomil; and recovering substantially pure olmesartan medoxomil.
14 . The process of claim 1 , wherein the substantially pure olmesartan medoxomil is obtained in a purity of greater than or equal to about 98%.
15 . The process of claim 14 , wherein the substantially pure olmesartan medoxomil is obtained in a purity of greater than or equal to about 99%.
16 . The process of claim 15 , wherein the substantially pure olmesartan medoxomil is obtained in a purity of greater than or equal to about 99.5%.
17 . The process of claim 16 , wherein the substantially pure olmesartan medoxomil contains less than about 0.5% of free olmesartan.
18 . The process of claim 17 , wherein the substantially pure olmesartan medoxomil contains less than about 0.1% of free olmesartan.
19 . Olmesartan medoxomil produced by the process of claim 1 .
20 . The olmesartan medoxomil of claim 19 , having a purity of greater than or equal to about 99%.
21 . Olmesartan medoxomil having a purity of greater than or equal to about 98%.
22 . The olmesartan medoxomil of claim 21 , having a purity of greater than or equal to about 99%.
23 . The olmesartan medoxomil of claim 21 , having a purity of greater than or equal to about 99.5%.
24 . The olmesartan medoxomil of claim 21 , having less than about 0.5% of free olmesartan.
25 . The olmesartan medoxomil of claim 21 , having less than about 0.1% of free olmesartan.
26 . A pharmaceutical composition comprising a therapeutically effective amount of the olmesartan medoxomil of claim 21 , and one or more pharmaceutically acceptable excipients.
27 . The pharmaceutical composition of claim 26 , wherein the olmesartan medoxomil is a micronized olmesartan medoxomil having a D 50 and D 90 particle size of less than about about 200 microns.
28 . The pharmaceutical composition of claim 26 , wherein the olmesartan medoxomil is a micronized olmesartan medoxomil having a D 50 and D 90 particle size of less than about 150 microns.
29 . The pharmaceutical composition of claim 26 , wherein the olmesartan medoxomil is a micronized olmesartan medoxomil having a D 50 and D 90 particle size of less than about 50 microns.
30 . The pharmaceutical composition of claim 26 , wherein the olmesartan medoxomil is a micronized olmesartan medoxomil having a D 50 and D 90 particle size of less than about 15 microns.
31 . A process for purifying olmesartan medoxomil, the process comprising (a) providing a solution comprising olmesartan medoxomil in a solvent system comprising a halogenated hydrocarbon-containing solvent and an ester-containing solvent; and (b) recovering substantially pure olmesartan medoxomil.
32 . The process of claim 31 , wherein the halogenated hydrocarbon-containing solvent is dichloromethane and the ester-containing solvent is ethyl acetate.
33 . The process of claim 32 , further comprising heating the solution to an elevated temperature; cooling the solution to induce precipitation of the olmesartan medoxomil; and recovering substantially pure olmesartan medoxomil.